

Comments from Mattias Perjos, CEO

Increased profitability, strong cash flow and higher customer satisfaction

"We delivered increased profitability and strong cash flow during the third quarter. This was partly driven by solid sales growth in Acute Care Therapies while Surgical Workflows reported stable order intake, mainly within operating room equipment. The situation for Life Science remains mixed – the high-margin Sterile Transfer category performed strongly, while the project-based and capital-intensive product category of WIS, which includes washer-disinfectors, was impacted by the persistently low level of investment activity in the pharma segment.

The adjusted EBITA margin strengthened sharply, rising to 15.1%, and was positively impacted by tariff refunds of SEK 45 M and year-on-year currency effects of approximately SEK 36 M. Even excluding these factors, the margin improved by more than 1 percentage point to 14.3%, which reflects the sustained positive underlying performance of the operations. The improvement was driven by a favorable mix, price discipline and productivity improvements. Improved profitability, together with a positive development in working capital, contributed to strong cash flow.

We initiated the launch of Cardiohelp II – the next generation of our ECLS therapy – in CE countries and Hong Kong during the quarter, and customer response has been very positive. We also received 510(k) clearance for a new Edi catheter, which can be used with our ventilators to provide breathing support to premature infants weighing as little as 500 grams. It is increasingly important for us as a trusted partner in healthcare to show how our solutions can help increase productivity. During the quarter, we launched Torin Plan Optimizer, an AI-powered system designed to manage resources more efficiently and make surgical workflows more predictable. We also continue to make clear progress on sustainability, reducing Scope 1 and 2 greenhouse gas emissions by over 20% year over year.

Getinge's greatest strength lies in the work my colleagues around the world do every day in close collaboration with our customers. Against the backdrop of an uncertain global environment, I am therefore particularly pleased that we have achieved all-time highs in both customer satisfaction and employee engagement. Although organic net sales growth year to date is somewhat below the guidance, our ongoing dialogue with customers supports our decision to maintain the full-year 2026 outlook of 3–5% organic net sales growth."

July – September 2026 in brief

- Net sales increased organically by 2.1% (9.5) and the order intake rose by 2.6% organically (4.7)
- Adjusted gross profit amounted to SEK 4,343 M (4,051) and the margin was 51.4% (49.2)
- Adjusted EBITA was SEK 1,278 M (1,079) and the margin 15.1% (13.1)
- Adjusted earnings per share amounted to SEK 3.10 (2.42)
- Free cash flow amounted to SEK 1,302 M (793)

January – September 2026 in brief

- Net sales increased organically by 2.5% (6.6) and the order intake rose by 4.2% organically (4.0)
- Adjusted gross profit amounted to SEK 12,817 M (12,570) and the margin was 52.8% (50.7)
- Adjusted EBITA was SEK 3,580 M (3,071) and the margin 14.8% (12.4)
- Adjusted earnings per share amounted to SEK 8.48 (6.84)
- Free cash flow amounted to SEK 3,145 M (1,462)

Outlook 2026: Net sales for 2026 are expected to increase by 3–5% organically, adjusted for the phase-out of Surgical Perfusion¹⁾

Summary of financial performance²⁾

SEK M	Jul-Sep 2026	Jul-Sep 2025	Jan-Sep 2026	Jan-Sep 2025	R12 Sep 2026	Jan-Dec 2025
Order intake	8,781	8,477	25,388	25,470	33,943	34,025
Organic change, %	2.6	4.7	4.2	4.0		3.5
Net sales	8,446	8,226	24,270	24,783	34,455	34,969
Organic change, %	2.1	9.5	2.5	6.6		4.9
Adjusted gross profit	4,343	4,051	12,817	12,570	17,854	17,607
Margin, %	51.4	49.2	52.8	50.7	51.8	50.4
Adjusted EBITDA	1,711	1,501	4,825	4,353	7,054	6,581
Margin, %	20.3	18.2	19.9	17.6	20.5	18.8
Adjusted EBITA	1,278	1,079	3,580	3,071	5,389	4,880
Margin, %	15.1	13.1	14.8	12.4	15.6	14.0
Adjusted EBIT	1,182	986	3,304	2,776	5,021	4,494
Margin, %	14.0	12.0	13.6	11.2	14.6	12.9
Operating profit (EBIT)	1,108	952	3,099	2,418	4,470	3,789
Margin, %	13.1	11.6	12.8	9.8	13.0	10.8
Profit before tax	974	789	2,698	1,938	3,905	3,145
Net profit for the period	726	576	1,967	1,407	2,836	2,276
Adjusted net profit for the period	850	668	2,316	1,880	3,529	3,093
Margin, %	10.1	8.1	9.5	7.6	10.2	8.8
Adjusted earnings per share, SEK	3.10	2.42	8.48	6.84	12.93	11.29
Earnings per share, SEK	2.64	2.08	7.20	5.10	10.39	8.29
Cash flow from operating activities	1,567	1,084	3,965	2,395	5,519	3,949
Free cash flow	1,302	793	3,145	1,462	4,335	2,652

1) For more information about the adjustment of the Organic change key ratio, refer to Other information on page 9

2) See page 3 for calculations of adjusted performance measures.

Group performance

Order intake

- The organic order intake for Acute Care Therapies increased, primarily in ECLS therapy consumables, Cardiac Assist and EVH consumables.
- Life Science's organic order intake declined slightly during the quarter. The positive performance in Bio-Processing and service did not offset the continuing decline in WIS.
- The organic order intake for Surgical Workflows increased, mainly driven by a strong performance in operating room equipment such as surgical tables and lamps.
- Geographically, the organic order intake trend was positive in all regions, with the US performing particularly well.

Order intake business areas, SEK M	Jul-Sep 2026	Jul-Sep 2025	Org Δ, %	Jan-Sep 2026	Jan-Sep 2025	Org Δ, %	R12 Sep 2026	Jan-Dec 2025
Acute Care Therapies	4,501	4,375	2.4	13,247	13,682	2.3	17,786	18,220
Life Science	1,224	1,232	-1.4	3,372	3,264	7.1	4,360	4,252
Surgical Workflows	3,056	2,869	4.5	8,768	8,524	6.1	11,797	11,553
Total	8,781	8,477	2.6	25,388	25,470	4.2	33,943	34,025

Order intake regions, SEK M	Jul-Sep 2026	Jul-Sep 2025	Org Δ, %	Jan-Sep 2026	Jan-Sep 2025	Org Δ, %	R12 Sep 2026	Jan-Dec 2025
Americas	3,996	3,781	3.8	11,622	11,634	5.4	15,417	15,429
APAC	1,668	1,615	2.2	4,633	4,782	1.9	6,162	6,311
EMEA	3,116	3,080	1.3	9,133	9,053	3.9	12,364	12,285
Total	8,781	8,477	2.6	25,388	25,470	4.2	33,943	34,025

Net sales

- Acute Care Therapies increased its net sales organically, primarily due to ECLS therapy consumables, intra-aortic balloon pumps in Cardiac Assist and stents.
- Organic net sales for Life Science fell slightly following a continuing decline in WIS and despite robust growth in Sterile Transfer.
- In Surgical Workflows, organic net sales rose slightly following growth in Infection Control and Digital Health Solutions.
- Positive organic growth in EMEA and Americas, with particularly strong sales in the US, France and Sweden. Sales declined in APAC, primarily driven by China and Japan.
- Recurring revenues increased in the quarter, driven by, for example, ECLS therapy, Sterile Transfer and service. Sales of capital goods declined in the quarter, above all related to WIS in Life Science.


Net sales business areas, SEK M	Jul-Sep 2026	Jul-Sep 2025	Org Δ, %	Jan-Sep 2026	Jan-Sep 2025	Org Δ, %	R12 Sep 2026	Jan-Dec 2025
Acute Care Therapies	4,516	4,339	4.5	13,081	13,594	2.0	18,161	18,675
Life Science	1,066	1,097	-3.6	3,170	3,171	3.5	4,497	4,498
Surgical Workflows	2,864	2,789	0.7	8,019	8,018	2.9	11,796	11,796
Total	8,446	8,226	2.1	24,270	24,783	2.5	34,455	34,969

Net sales regions, SEK M	Jul-Sep 2026	Jul-Sep 2025	Org Δ, %	Jan-Sep 2026	Jan-Sep 2025	Org Δ, %	R12 Sep 2026	Jan-Dec 2025
Americas	3,886	3,723	2.8	11,213	11,617	1.8	15,282	15,686
APAC	1,563	1,655	-6.5	4,405	4,849	-4.3	6,498	6,943
EMEA	2,997	2,848	6.3	8,652	8,317	7.4	12,675	12,340
Total	8,446	8,226	2.1	24,270	24,783	2.5	34,455	34,969

Net sales specified by capital goods and recurring revenue, SEK M	Jul-Sep 2026	Jul-Sep 2025	Org Δ, %	Jan-Sep 2026	Jan-Sep 2025	Org Δ, %	R12 Sep 2026	Jan-Dec 2025
Capital goods	2,498	2,675	-6.3	7,071	7,785	-5.1	11,254	11,968
Recurring revenue ¹⁾	5,948	5,551	6.2	17,199	16,999	6.0	23,201	23,001
Total	8,446	8,226	2.1	24,270	24,783	2.5	34,455	34,969

1) Consumables, service and spare parts

Net sales – bridge between Q3 2025 and Q3 2026



- Net sales increased by SEK 220 M, corresponding to 2.7%.
- Exchange rates had an impact of SEK +82M on sales, corresponding to +1.0%.
- Successful efforts with price adjustments and volumes had an impact of SEK +173 M on sales, corresponding to +2.1%.

Earnings trend

- Currency effects impacted adjusted gross profit by SEK +85 M and adjusted EBITA by SEK +36 M compared with last year.
- Adjusted gross profit increased by SEK 292 M, of which the remaining tariff refunds had an impact of approximately SEK +45 M and tariff costs of approximately SEK -107 M (Q3 2025 SEK -108 M). Coupled with continued successful price adjustments, productivity and a positive mix, the margin improved by 2.2 percentage points.
- Adjusted EBITA increased by SEK 199 M, primarily due to improved gross profit. The margin increased by 2.0 percentage points.
- Acquisition and restructuring costs are among other things related to the ongoing rationalizations in the organization.
- Net financial items decreased to SEK -134 M, mainly as a result of lower average interest year-on-year.
- The tax rate for the first three quarters was 27.1%.

SEK M	Jul-Sep 2026	Jul-Sep 2025	Jan-Sep 2026	Jan-Sep 2025	R12 Sep 2026	Jan-Dec 2025
Net sales	8,446	8,226	24,270	24,783	34,455	34,969
Adjusted gross profit	4,343	4,051	12,817	12,570	17,854	17,607
Margin, %	51.4	49.2	52.8	50.7	51.8	50.4
Adjusted operating expenses	-2,633	-2,550	-7,991	-8,217	-10,800	-11,026
Adjusted EBITDA	1,711	1,501	4,825	4,353	7,054	6,581
Margin, %	20.3	18.2	19.9	17.6	20.5	18.8
Depreciation, amortization and write-downs of intangible assets and tangible assets ¹⁾	-433	-422	-1,245	-1,282	-1,665	-1,702
Adjusted EBITA	1,278	1,079	3,580	3,071	5,389	4,880
Margin, %	15.1	13.1	14.8	12.4	15.6	14.0
Amortization and write-down of acquired intangible assets ¹⁾	-96	-93	-276	-294	-368	-386
Adjusted EBIT	1,182	986	3,304	2,776	5,021	4,494
Margin, %	14.0	12.0	13.6	11.2	14.6	12.9
B Acquisition and restructuring costs	-74	-33	-172	-359	-211	-397
C Other items affecting comparability ²⁾	-	-	-33	-	-340	-307
Operating profit (EBIT)	1,108	952	3,099	2,418	4,470	3,789
Net financial items	-134	-163	-401	-480	-565	-644
Profit before tax	974	789	2,698	1,938	3,905	3,145
Adjusted profit before tax (adjusted for A, B and C)	1,144	916	3,179	2,591	4,824	4,236
Margin, %	13.6	11.1	13.1	10.5	14.0	12.1
Taxes	-248	-214	-731	-531	-1,069	-869
D Tax on adjustment items ²⁾	-47	-35	-133	-180	-227	-273
Adjusted net profit for the period (adjusted for A, B, C and D)	850	668	2,316	1,880	3,529	3,093
Margin, %	10.1	8.1	9.5	7.6	10.2	8.8
Of which, attributable to Parent Company shareholders	843	658	2,310	1,863	3,522	3,076
Average number of shares, thousands	272,370	272,370	272,370	272,370	272,370	272,370
Adjusted earnings per share, SEK (adjusted for A, B, C and D)	3.10	2.42	8.48	6.84	12.93	11.29

1) Excluding items affecting comparability (see Note 4 Depreciation, amortization and write-downs)


2) See Note 6 Adjustment items

Adjusted EBITA per business area¹⁾

SEK M	Jul-Sep 2026	Jul-Sep 2025	Jan-Sep 2026	Jan-Sep 2025	R12 Sep 2026	Jan-Dec 2025
Acute Care Therapies	975	763	2,940	2,624	4,080	3,763
Margin, %	21.6	17.6	22.5	19.3	22.5	20.2
Life Science	125	141	367	318	539	490
Margin, %	11.7	12.9	11.6	10.0	12.0	10.9
Surgical Workflows	284	263	596	453	1,221	1,077
Margin, %	9.9	9.4	7.4	5.6	10.3	9.1
Group functions and other (incl. eliminations)	-106	-89	-324	-323	-451	-450
Total	1,278	1,079	3,580	3,071	5,389	4,880
Margin, %	15.1	13.1	14.8	12.4	15.6	14.0

1) See Note 4 Depreciation, amortization and write-downs and Note 6 Adjustment items for other items affecting comparability

Adjusted EBITA – bridge between Q3 2025 and Q3 2026



- Adjusted EBITA for Acute Care Therapies rose by SEK 212 M, mainly due to continued successful price adjustments, higher sales and a favorable mix. The margin improved by 4.0 percentage points.
- Life Science's adjusted EBITA decreased by SEK -16 M, mainly attributable to a higher selling and administrative expenses. The margin fell by 1.2 percentage points.
- Adjusted EBITA for Surgical Workflows increased by SEK 21 M, mainly due to price adjustments and tariff refunds. The margin improved by 0.5 percentage points.
- Costs in Group functions and other were in line with previous quarters this year, but were higher than the year-earlier quarter.

- Adjusted operating expenses for selling and administration increased by 3.0%. Organically they increased by 1.8%.
- The year-on-year difference for other operating income and expenses was mainly attributable to currency effects related to operating receivables and liabilities in foreign currency.

Adjusted operating expenses

(excluding depreciation, amortization and write-downs, and other items affecting comparability)¹⁾

SEK M	Jul-Sep 2026	Jul-Sep 2025	Jan-Sep 2026	Jan-Sep 2025	R12 Sep 2026	Jan-Dec 2025
Selling expenses	-1,282	-1,256	-3,904	-3,978	-5,270	-5,345
Administrative expenses	-1,033	-990	-3,169	-3,100	-4,251	-4,182
Selling and administrative expenses	-2,315	-2,246	-7,073	-7,078	-9,521	-9,527
Research and development costs	-336	-286	-982	-913	-1,313	-1,244
Other operating income and expenses	18	-17	63	-226	34	-255
Total	-2,633	-2,550	-7,991	-8,217	-10,800	-11,026

1) See Note 4 Depreciation, amortization and write-downs and Note 6 Adjustment items for other items affecting comparability

- Costs for R&D were 7.4% higher year-on-year.
- Capitalized development costs were 10.9% lower compared with last year.
- The year-on-year difference was mainly due to higher activity.
- Amortization and write-down of capitalized development costs amounted to SEK -94 M (-98), of which SEK -6 M write-down (-4).

Research and development

SEK M	Jul-Sep 2026	Jul-Sep 2025	Jan-Sep 2026	Jan-Sep 2025	R12 Sep 2026	Jan-Dec 2025
Research and development costs	-466	-434	-1,408	-1,407	-1,921	-1,921
Amortization, depreciation and write-downs	-27	-21	-68	-55	-188	-175
Research and development costs, gross	-494	-454	-1,475	-1,462	-2,109	-2,096
<i>In relation to net sales, %</i>	5.8	5.5	6.1	5.9	6.1	6.0
Capitalized development costs	131	147	426	494	575	643
<i>In relation to net sales, %</i>	1.5	1.8	1.8	2.0	1.7	1.8
Research and development costs, net	-363	-307	-1,049	-968	-1,534	-1,452
Amortization and write-down of capitalized development costs¹⁾	-94	-98	-265	-297	-397	-430

1) Capitalized development projects

- Exchange-rate fluctuations, meaning translation and transaction effects, impacted adjusted gross profit by SEK +85 M compared with last year, of which SEK +37 M in translation effects and SEK +48 M in transaction effects.
- The change in adjusted EBITA attributable to currency effects was SEK +36 M, of which SEK +10 M arose from translation effects and SEK +26 M from the net of transaction effects and revaluation of operating receivables and liabilities in foreign currency.

Currency impact

SEK M	Jul-Sep 2026	Jan-Sep 2026	R12 Sep 2026
Net sales	82	-1,025	-2,048
Adjusted gross profit	85	-583	-1,156
Adjusted EBITDA	37	-196	-550
Adjusted EBITA	36	-159	-474
Adjusted EBIT	34	-144	-448

- Free cash flow increased considerably compared with last year. It was positively impacted by the strong operating profit and changes in working capital.
- The financial position remains solid.

Cash flow and financial position¹⁾

SEK M	Jul-Sep 2026	Jul-Sep 2025	Jan-Sep 2026	Jan-Sep 2025	R12 Sep 2026	Jan-Dec 2025
Cash flow before changes in working capital	1,165	1,141	3,495	3,327	5,305	5,137
Changes in working capital	402	-56	470	-932	214	-1,188
Net investments in non-current assets	-265	-292	-820	-933	-1,184	-1,297
Free cash flow	1,302	793	3,145	1,462	4,335	2,652
Net interest-bearing cash/debt			10,397	11,061	10,397	9,840
<i>In relation to adjusted EBITDA¹⁾ R12M, multiple</i>			1.5	1.6	1.5	1.5
Net interest-bearing cash/debt, excl. pension provisions			8,076	8,582	8,076	7,482
<i>In relation to adjusted EBITDA¹⁾ R12M, multiple</i>			1.1	1.2	1.1	1.1

1) See Note 6 Adjustment items for items affecting comparability and Note 8 for alternative performance measures

Sustainability developments

This interim report reflects Getinge's double materiality assessment and is based on the ESRS structure to present the company's impact, risks and opportunities from a social, environmental and governance perspective. The purpose of the sustainability KPIs is to monitor trends over time. Getinge continuously works to minimize the negative impact on people and the environment and to generate sustainable value for customers, employees and other stakeholders.

- Getinge's energy efficiency measures continued to yield results in the quarter in terms both of energy consumption and of lower Scope 1 & 2 emissions from production facilities. The increase in the share of renewable electricity and gas also contributed to lower emissions for R12 Sep 2026.
- Water consumption is mainly related to testing in production and therefore varies over time. The higher outcome for R12 Sep 2026 compared with last year mainly derived from increased production.
- The employee engagement index was updated with the results of the employee survey conducted in Q2 2026. The outcome was 74, which reflects a continued positive trend and resulted in a score of 73.5 for employee engagement for R12 Sep 2026.
- The Work Related Accident Rate (WRAR) outcome for R12 Sep 2026 continued to show a positive trend.
- From 2026, the definition of the regulatory compliance KPI has been revised to focus on major observations from regulators and notified bodies only. The KPI increased slightly in R12 Sep 2026 due to the date that the audits were performed.
- Training in business ethics has had a positive development R12 Sep 2026 with 96% of employees that have completed Getinge's Code of Conduct workshop.
- Sustainability reporting now includes Pennamed from the acquisition date.

Key areas	R12 Sep 2026 ¹⁾	R12 Sep 2025 ¹⁾	Δ, % ²⁾	Jan-Dec 2025	Δ, % ³⁾
Environment, Climate & Energy					
Scope 1 & 2 GHG emissions in production, ton CO ₂ equivalents ⁹⁾	3,990	5,026	-20.6	4,913	-18.8
Total energy consumption in production, MWh ⁹⁾	75,705	82,375	-8.1	80,887	-6.4
Percentage of renewable energy of total energy, % ⁹⁾	72	69	3.0*	69	3.0*
Water consumption in sites located in water scarce areas, m ³ 4), 9)	117,480	107,318	9.5	114,691	2.4
Social					
Own workforce					
Employee engagement, % ⁵⁾	73.5	72	1.5*	73	0.5*
Percentage of female employees, % ⁶⁾	38.6	37.9	0.7*	38.2	0.4*
Percentage of female managers, % ⁶⁾	35.1	34.3	0.8*	34.1	1.0*
Work Related Accident Rate, WRAR ⁸⁾	0.5	0.84	-40.5	0.59	-15.3
Consumers and end-users					
Regulatory compliance, audit findings per audit for quality systems ⁷⁾	0.8	-	-	0.7	5.5
Product quality, field actions per SEK billion in net revenue	1.1	1.1	0	1.0	13.4
Online customer training	55,363	50,815	9.0	53,238	4.0
Governance					
Business ethics					
Percentage of employees who completed training in business ethics, % ⁹⁾	96	-	-	-	-

*) Change in percentage points

1) R12 = Rolling 12 months

2) Index R12 Sep 2026/ R12 Sep 2025

3) Index R12 Sep 2026/ Jan-Dec 2025

4) The production sites in scope are those located in areas with high or extremely high water stress according to the WRI Water Risk Atlas tool Acqueduct, which are eight sites.



5) Measured and updated every six months

6) Amount at end of period

7) Data available from 2025. According to the previous definition of the KPI, the outcome was 1.4 audit findings for the full-year 2025

8) Outcome for Jan-Sep 2026. From 2026, the KPI represents the percentage of employees who completed Getinge's new Code of Conduct workshop. The outcome for the previous training in business ethics was 92% for the full-year 2025

9) Four legal entities joined the Group by acquisition, and data was updated in 2025. See Getinge's Annual Report 2025 for more information. Data for Pennamed is included from the acquisition date 2026



Acute Care Therapies

Acute Care Therapies offers world-leading solutions for life support in acute health conditions. The offering includes solutions for cardiovascular procedures, efficient handling of organs for transplantation and a broad selection of products and therapies for intensive care.

- The organic order intake for Acute Care Therapies increased, primarily in consumables in ECLS therapy, Cardiac Assist and EVH.
- Geographically, the organic order intake grew mainly in EMEA, following a solid performance in several countries. APAC declined slightly despite strong growth in China.

- Acute Care Therapies increased its net sales organically, primarily due to ECLS therapy consumables, intra-aortic balloon pumps in Cardiac Assist and stents.
- Sales grew organically in all regions. The US and India made significant contributions.
- Recurring revenue increased primarily as a result of ECLS therapy consumables, stents and service. Capital goods declined, mainly driven by lower sales of ventilators despite an increase in ECLS and Cardiac Assist.

- The adjusted gross margin improved by 3.0 percentage points, largely due to continued successful price adjustments, higher sales and a favorable mix.
- Adjusted selling and administrative expenses increased organically by 0.5%. Inorganically, these expenses increased by 1.7%.
- Adjusted EBITA for Acute Care Therapies rose by SEK 212 M, mainly due to improved gross profit. The margin improved by 4.0 percentage points.
- Currency effects impacted sales by SEK +56 M, adjusted gross profit by SEK +54 M and adjusted EBITA by SEK +25 M compared with last year.

Order intake and net sales

Order intake regions, SEK M	Jul-Sep 2026	Jul-Sep 2025	Org Δ, %	Jan-Sep 2026	Jan-Sep 2025	Org Δ, %	R12 Sep 2026	Jan-Dec 2025
Americas	2,315	2,261	0.5	6,888	7,380	-1.3	9,299	9,791
APAC	978	964	-0.3	2,726	2,785	2.9	3,523	3,583
EMEA	1,208	1,150	8.7	3,634	3,516	9.7	4,964	4,846
Total	4,501	4,375	2.4	13,247	13,682	2.3	17,786	18,220

Net sales regions, SEK M	Jul-Sep 2026	Jul-Sep 2025	Org Δ, %	Jan-Sep 2026	Jan-Sep 2025	Org Δ, %	R12 Sep 2026	Jan-Dec 2025
Americas	2,414	2,289	4.0	6,908	7,357	-0.8	9,444	9,893
APAC	930	922	0.3	2,673	2,837	0.0	3,765	3,928
EMEA	1,172	1,128	9.3	3,499	3,400	10.1	4,953	4,854
Total	4,516	4,339	4.5	13,081	13,594	2.0	18,161	18,675

Net sales specified by capital goods and recurring revenue, SEK M	Jul-Sep 2026	Jul-Sep 2025	Org Δ, %	Jan-Sep 2026	Jan-Sep 2025	Org Δ, %	R12 Sep 2026	Jan-Dec 2025
Capital goods	874	890	-0.6	2,526	2,873	-6.7	3,921	4,267
Recurring revenue ¹⁾	3,642	3,449	5.9	10,555	10,722	4.3	14,241	14,407
Total	4,516	4,339	4.5	13,081	13,594	2.0	18,161	18,675

1) Consumables, service and spare parts

Earnings trend¹⁾

SEK M	Jul-Sep 2026	Jul-Sep 2025	Jan-Sep 2026	Jan-Sep 2025	R12 Sep 2026	Jan-Dec 2025
Net sales	4,516	4,339	13,081	13,594	18,161	18,675
Adjusted gross profit	2,689	2,456	8,062	7,951	11,008	10,897
Margin, %	59.6	56.6	61.6	58.5	60.6	58.4
Adjusted EBITDA	1,199	972	3,573	3,271	4,918	4,616
Margin, %	26.5	22.4	27.3	24.1	27.1	24.7
Depreciation, amortization and write-downs of intangible assets and tangible assets	-223	-209	-632	-647	-838	-853
Adjusted EBITA	975	763	2,940	2,624	4,080	3,763
Margin, %	21.6	17.6	22.5	19.3	22.5	20.2

1) See Note 4 Depreciation, amortization and write-downs and Note 6 Adjustment items for other items affecting comparability

Events in the business area in the quarter

- We received 510(k) clearance from the US FDA for a new Edi catheter, which can be used with Getinge's ventilators to provide breathing support to premature infants weighing between 500 and 1,000 grams.
- The launch of Cardiohelp II – Getinge's next generation of ECLS therapy – was initiated in CE countries and Hong Kong during the quarter. Customer response has been very positive.

Life Science

Life Science offers a comprehensive range of equipment, technical expertise and consultation to prevent contamination in pharmaceutical and medical device production and with the aim to strengthen integrity of results in biomedical research.

- Life Science's organic order intake declined slightly during the quarter. The positive performance in Bio-Processing and service did not offset the continuing decline in WIS.
- The organic order intake increased only in Americas, with the US displaying positive signs through a strong performance in Bio-Processing and WIS.

- Organic net sales for Life Science fell slightly following a continuing decline in WIS and despite robust growth in Sterile Transfer.
- Organic sales increased in all regions except APAC, where mainly China and Japan declined.
- Recurring revenue continued to show double-digit growth, while capital goods did the opposite. The decline in capital goods was primarily driven by WIS.

- The adjusted gross margin increased by 1.9 percentage points, mainly attributable to a favorable mix and price adjustments.
- Adjusted selling and administrative expenses increased organically by 9.1%. Inorganically, these expenses increased by 9.9%.
- Life Science's adjusted EBITA decreased by SEK 16 M, mainly attributable to higher selling and administrative expenses. The margin fell by 1.2 percentage points.
- Currency effects impacted sales by SEK +8 M, adjusted gross profit by SEK +20 M and adjusted EBITA by SEK +15 M compared with last year.

Order intake and net sales

Order intake regions, SEK M	Jul-Sep 2026	Jul-Sep 2025	Org Δ, %	Jan-Sep 2026	Jan-Sep 2025	Org Δ, %	R12 Sep 2026	Jan-Dec 2025
Americas	470	414	12.1	1,332	1,124	25.0	1,677	1,469
APAC	123	145	-19.3	411	399	7.3	532	520
EMEA	631	673	-5.8	1,629	1,742	-4.6	2,151	2,263
Total	1,224	1,232	-1.4	3,372	3,264	7.1	4,360	4,252

Net sales regions, SEK M	Jul-Sep 2026	Jul-Sep 2025	Org Δ, %	Jan-Sep 2026	Jan-Sep 2025	Org Δ, %	R12 Sep 2026	Jan-Dec 2025
Americas	412	391	4.3	1,187	1,179	6.0	1,667	1,660
APAC	122	192	-38.5	368	438	-12.7	532	603
EMEA	532	514	3.3	1,616	1,553	6.0	2,298	2,235
Total	1,066	1,097	-3.6	3,170	3,171	3.5	4,497	4,498

Net sales specified by capital goods and recurring revenue, SEK M	Jul-Sep 2026	Jul-Sep 2025	Org Δ, %	Jan-Sep 2026	Jan-Sep 2025	Org Δ, %	R12 Sep 2026	Jan-Dec 2025
Capital goods	284	460	-39.1	966	1,274	-21.6	1,564	1,872
Recurring revenue ¹⁾	781	638	22.0	2,204	1,897	20.3	2,933	2,626
Total	1,066	1,097	-3.6	3,170	3,171	3.5	4,497	4,498

1) Consumables, service and spare parts

Earnings trend¹⁾

SEK M	Jul-Sep 2026	Jul-Sep 2025	Jan-Sep 2026	Jan-Sep 2025	R12 Sep 2026	Jan-Dec 2025
Net sales	1,066	1,097	3,170	3,171	4,497	4,498
Adjusted gross profit	409	401	1,231	1,208	1,699	1,676
Margin, %	38.4	36.5	38.8	38.1	37.8	37.3
Adjusted EBITDA	177	197	522	484	750	712
Margin, %	16.6	18.0	16.5	15.3	16.7	15.8
Depreciation, amortization and write-downs of intangible assets and tangible assets	-53	-56	-155	-167	-211	-222
Adjusted EBITA	125	141	367	318	539	490
Margin, %	11.7	12.9	11.6	10.0	12.0	10.9

1) See Note 4 Depreciation, amortization and write-downs and Note 6 Adjustment items for other items affecting comparability

Events in the business area in the quarter

- Despite a challenging global investment climate in pharma, the WIS product segment grew in the US during the quarter. Growth was supported by the work done to optimize Getinge's US Life Science organization to meet increasing customer investments.
- The nuclear medicine therapy market continues to expand rapidly and Getinge is a supplier of containment and transfer equipment to this value chain.

Surgical Workflows

Surgical Workflows offers products and solutions to serve as an end-to-end partner for optimizing the quality, safety and capacity usage of the sterile supply departments and operating rooms.

- The organic order intake for Surgical Workflows increased, mainly driven by a strong performance in operating room equipment such as surgical tables and lamps.
- Growth was particularly strong in North America, mainly in operating tables and capital goods in Infection Control.

- In Surgical Workflows, organic net sales rose slightly following growth in Infection Control and Digital Health Solutions.
- Geographically, growth was high in EMEA, mainly in Surgical Workplaces and Digital Health Solutions. In APAC, the only product category that grew was Infection Control.
- The increase in sales of capital goods was primarily driven by Infection Control. Recurring revenue was largely unchanged.

- The adjusted gross margin increased by 0.7 percentage points, mainly due to price adjustments and tariff refunds.
- Adjusted selling and administrative expenses increased organically by 1.2%. Inorganically, these expenses increased by 2.8%.
- Adjusted EBITA for Surgical Workflows increased by SEK 21 M, mainly attributable to higher gross profit. The margin improved by 0.5 percentage points.
- Currency effects impacted sales by SEK +18 M, adjusted gross profit by SEK +11 M and adjusted EBITA by SEK +1 M compared with last year.

Order intake and net sales

Order intake regions, SEK M	Jul-Sep 2026	Jul-Sep 2025	Org Δ, %	Jan-Sep 2026	Jan-Sep 2025	Org Δ, %	R12 Sep 2026	Jan-Dec 2025
Americas	1,211	1,106	7.5	3,403	3,130	14.1	4,441	4,168
APAC	568	506	13.0	1,496	1,598	-1.2	2,106	2,208
EMEA	1,277	1,257	-1.5	3,869	3,796	2.6	5,250	5,176
Total	3,056	2,869	4.5	8,768	8,524	6.1	11,797	11,553

Net sales regions, SEK M	Jul-Sep 2026	Jul-Sep 2025	Org Δ, %	Jan-Sep 2026	Jan-Sep 2025	Org Δ, %	R12 Sep 2026	Jan-Dec 2025
Americas	1,060	1,043	-0.4	3,118	3,081	6.4	4,171	4,133
APAC	511	540	-6.6	1,364	1,575	-9.4	2,201	2,412
EMEA	1,293	1,206	5.0	3,537	3,363	5.6	5,425	5,251
Total	2,864	2,789	0.7	8,019	8,018	2.9	11,796	11,796

Net sales specified by capital goods and recurring revenue, SEK M	Jul-Sep 2026	Jul-Sep 2025	Org Δ, %	Jan-Sep 2026	Jan-Sep 2025	Org Δ, %	R12 Sep 2026	Jan-Dec 2025
Capital goods	1,340	1,325	1.3	3,579	3,638	1.9	5,769	5,829
Recurring revenue ¹⁾	1,524	1,465	0.2	4,440	4,380	3.8	6,027	5,967
Total	2,864	2,789	0.7	8,019	8,018	2.9	11,796	11,796

1) Consumables, service and spare parts

Earnings trend¹⁾

SEK M	Jul-Sep 2026	Jul-Sep 2025	Jan-Sep 2026	Jan-Sep 2025	R12 Sep 2026	Jan-Dec 2025
Net sales	2,864	2,789	8,019	8,018	11,796	11,796
Adjusted gross profit	1,245	1,194	3,523	3,410	5,147	5,034
Margin, %	43.5	42.8	43.9	42.5	43.6	42.7
Adjusted EBITDA	439	419	1,047	915	1,828	1,697
Margin, %	15.3	15.0	13.1	11.4	15.5	14.4
Depreciation, amortization and write-downs of intangible assets and tangible assets	-155	-155	-451	-463	-608	-619
Adjusted EBITA	284	263	596	453	1,221	1,077
Margin, %	9.9	9.4	7.4	5.6	10.3	9.1

1) See Note 4 Depreciation, amortization and write-downs and Note 6 Adjustment items for other items affecting comparability

Events in the business area in the quarter

- The launch of Torin Plan Optimizer, an AI-powered decision support solution for surgical planning based on operating rooms, surgeon and surgical team availability and post-operative capacity. This enables better resource utilization, which is much needed in hospitals.

Other information

Events after the end of the reporting period

- Eric Honroth, President Life Science and member of the Executive Team, informed about his resignation in early October to accept an external opportunity. Getinge has started the process of identifying a successor and will evaluate internal and external candidates. Eric Honroth will continue to serve in his current role until his departure on October 31, 2026. To ensure continuity, an internal candidate has been appointed as interim President of Life Science, effective November 1.
- The geopolitical uncertainty and changing global environment continue to dominate the market. We are monitoring developments closely and continuously assessing the potential impact on our operations.

Significant events earlier in the year

During the second quarter, Getinge received a refund of previously paid US tariffs imposed under the International Emergency Economic Powers Act (IEEPA), resulting in a positive earnings impact of SEK 336 million. No other individual events occurring in earlier quarters of the year are considered to have had, or are expected to have, a material effect on the financial statements, nor are they of such significance as to be necessary for understanding the changes in the Company's financial position and results of operations since the end of the latest financial year.

Seasonal variations

Getinge's sales and earnings are affected by seasonal variations. The highest net sales are usually generated in the fourth quarter, followed by the second, third and first quarters. The shares of sales derived from capital goods and recurring revenue also normally changes during the year, with a higher share of sales of capital goods toward the end of the year.

Transactions with related parties

Getinge carried out normal commercial transactions with companies in the Carl Bennet AB sphere, which comprised the sale and purchase of goods and services. In addition, no other significant transactions with related parties occurred during the period other than transactions with subsidiaries.

Forward-looking information

This report contains forward-looking information based on the current expectations of company management. Although management deems that the expectations presented by such forward-looking information are reasonable, no guarantee can be given that these expectations will prove correct. Accordingly, the actual future outcome could vary considerably compared with what is stated in the forward-looking information, due to such factors as changed conditions regarding finances, market and competition, changes in legal and regulatory requirements and other political measures, and fluctuations in exchange rates.

Update of Organic change key ratio

The definition of Organic change has been updated from the first quarter of 2026 to also adjust for phase-outs of product categories. The change has been made to provide a more fair presentation of underlying growth even when phase-outs are currently being made. Quarterly comparative figures for 2025, excluding the Surgical Perfusion product category, are published on Getinge's website under Reports and Presentations, <https://www.getinge.com/int/company/investors/reports-presentations/>. Surgical Perfusion's sales in 2026 are expected to decline from approximately SEK 250 M to SEK 50 M.

Getinge's financial targets 2024–2028 and dividend policy

- Average adjusted earnings per share growth: >12%*
- Getinge's dividend policy is to pay dividends of 30-50% of net profit to shareholders.

Getinge's sustainability targets

Environment

- Reduce Scope 1 and 2 emissions by 90% by 2030**
- Reduce Scope 3 emissions by 25% by 2030, and by 90% by 2050**
- Reduce energy consumption in production by 20% by 2030**
- Reduce water consumption in sites located in water scarce areas by 20% by 2030**
- No waste to landfill by 2030, excluding material required by local regulations to be landfilled

Social

- Employee engagement: >70%
- Maintain work-related accidents in relation to working hours (Work Related Accident Rate, WRAR) at less than 1.
- Ensure equal employment opportunity and non-discrimination across all levels of the organization. Follow-up % female vs male managers and employees
- Quality regulatory compliance, audit results/inspection: <1.2 deviation

Governance

- All employees are properly trained in Business ethics

*Base year 2023

**Base year 2021

Nomination Committee ahead of 2027 Annual General Meeting

In accordance with the principles adopted at the 2020 Annual General Meeting, the Nomination Committee shall consist of members appointed by the four largest shareholders in terms of voting rights as of August 31 of each year, based on a list of owner-registered shareholders from Euroclear Nordics AB or other reliable ownership information, as well as the Chairman of the Board of Directors. In addition, if the Chairman of the Board in consultation with the member appointed by the largest shareholder in terms of voting rights deems it appropriate, it shall include an, in relation to the company and its major shareholders, independent representative of the minority shareholders as a member of the Nomination Committee.

Getinge's Nomination Committee ahead of the 2027 Annual General Meeting has been appointed and consists of the company's Chairman Johan Malmquist, and representatives from the following shareholders, listed in order of voting power.

- **Carl Bennet AB:** Carl Bennet, Chairman of the Nomination Committee
- **AMF Pension & Fonder:** Sophie Larsén
- **Fourth Swedish National Pension Fund:** Anna Magnusson
- **Carnegie fonder:** Anna Strömberg

Shareholders who wish to submit proposals to Getinge's 2027 Nomination Committee can contact the Nomination Committee by e-mail at valberedningen@getinge.com or by mail to the following address: Getinge AB, Att: Nomination Committee, Box 8861, SE-402 72 Gothenburg, SWEDEN. Proposals must be received by the Nomination Committee no later than January 15, 2027, in order to ensure that they are addressed by the Committee.

2027 Annual General Meeting

Getinge AB's Annual General Meeting will be held on April 20, 2027, in Halmstad, Sweden.

Shareholders who wish to have a matter addressed at the Annual General Meeting may submit their proposal to Getinge's Chairman of the Board via e-mail:

arenden.bolagsstamma@getinge.com, or by mail to the following address: Getinge AB, Att: Bolagsstämmoärenden, Box 8861, SE-402 72 Gothenburg, SWEDEN. To ensure inclusion in the notice and the agenda of the AGM, proposals must be received by the company no later than March 2, 2027.

Risk management

Risk management

Getinge operates in a global market and has a strong presence in a large number of countries. Active risk management at all levels is important in order for Getinge to successfully continue to create innovative products and services that improve people's quality of life.

Risk management framework

Getinge's three business areas and the Global Sales and Service organization are responsible for identifying and managing risks in their respective areas. The corporate and Group support functions support these units by providing governance, developing processes and promoting synergies in their specific areas of competence. In addition, several forums and groups have been established that focus on certain areas and identify and monitor specific types of risks.

Getinge has an Enterprise Risk Management (ERM) process covering all business areas, the global sales and service organization and the corporate and Group support functions. The Executive Team evaluates the material risks identified in the ERM process and its potential impacts, and decides on actions to mitigate risks and their consequences. The results of the ERM process serve as a key basis in determining the focus areas for Corporate Internal Audit.

Risk assessment

The most relevant risks are presented in Getinge's 2025 Annual Report, meaning that the list does not constitute a complete account of all of the risks to which the Group is exposed. The risks are divided into three categories:

- **External** – risks that cannot be controlled, but that are monitored and prepared for in order to optimize outcomes and turn risks into opportunities.
- **Operational** – Risks that are largely controllable and preventable, mainly related to processes, assets and employees.
- **Strategic** – risks that make it more difficult to achieve the strategic targets. These risks are to be managed by balancing risks and the potential for maximizing advantages.

Assurance

The Board of Directors and CEO assure that the interim report provides a true and fair review of the Parent Company and the Group's operations, position and earnings and describes the material risks and uncertainties faced by the Parent Company and the Group.

Gothenburg, October 21, 2026

Johan Malmquist
Chairman,
AGM-elected Board member

Carl Bennet
Vice Chairman,
AGM-elected Board member

Johan Bygge
AGM-elected Board member

Cecilia Daun Wennborg
AGM-elected Board member

Ulrika Dellby
AGM-elected Board member

Dan Frohm
AGM-elected Board member

Mattias Perjos
President & CEO,
AGM-elected Board member

Kristian Samuelsson
AGM-elected Board member

Camilla Sylvest
AGM-elected Board member

Fredrik Brattborn
Board member
Representative of the Swedish
Metalworkers' Union

Ida Ekman
Board member
Representative of Unionen

AUDITOR'S REPORT

Getinge AB (publ), reg. no. 556408-5032

Introduction

We have reviewed the condensed interim report for Getinge AB (publ) as at September 30, 2026 and for the nine months period then ended. The Board of Directors and the Managing Director are responsible for the preparation and presentation of this interim report in accordance with IAS 34 and the Swedish Annual Accounts Act. Our responsibility is to express a conclusion on this interim report based on our review.

Scope of review

We conducted our review in accordance with the International Standard on Review Engagements, ISRE 2410 *Review of Interim Financial Statements Performed by the Independent Auditor of the Entity*. A review consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with International Standards on Auditing and other generally accepted auditing standards in Sweden. The procedures performed in a review do not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

Conclusion

Based on our review, nothing has come to our attention that causes us to believe that the interim report is not prepared, in all material respects, in accordance with IAS 34 and the Swedish Annual Accounts Act regarding the Group, and in accordance with the Swedish Annual Accounts Act regarding the Parent Company.

Gothenburg, October 21, 2026

Ernst & Young AB

Fredrik Norrman
Authorized Public Accountant

Consolidated financial statements

Condensed consolidated income statement

SEK M	Note	Jul-Sep 2026	Jul-Sep 2025	Jan-Sep 2026	Jan-Sep 2025	Jan-Dec 2025
Net sales	2, 3	8,446	8,226	24,270	24,783	34,969
Cost of goods sold		-4,338	-4,411	-12,140	-12,932	-18,315
Gross profit	2, 3, 4	4,108	3,815	12,130	11,851	16,654
Selling expenses		-1,453	-1,416	-4,394	-4,476	-6,050
Administrative expenses		-1,128	-1,090	-3,446	-3,405	-4,587
Research and development costs		-363	-307	-1,049	-968	-1,452
Acquisition costs		-33	-11	-64	-14	-24
Restructuring costs		-41	-23	-108	-345	-374
Other operating income and expenses		18	-17	30	-226	-379
Operating profit (EBIT)	3, 4	1,108	952	3,099	2,418	3,789
Net financial items	3	-134	-163	-401	-480	-644
Profit after financial items	3	974	789	2,698	1,938	3,145
Taxes		-248	-214	-731	-531	-869
Net profit for the period		726	576	1,967	1,407	2,276
Attributable to:						
Parent Company shareholders		719	566	1,962	1,390	2,258
Non-controlling interests		6	10	6	17	17
Net profit for the period		726	576	1,967	1,407	2,276
Earnings per share, SEK ^{1) 2)}		2.64	2.08	7.20	5.10	8.29
Weighted average number of shares for calculation of earnings per share (000s)		272,370	272,370	272,370	272,370	272,370

1) Before and after dilution

2) Attributable to the Parent Company shareholders

Consolidated statement of comprehensive income

SEK M	Jul-Sep 2026	Jul-Sep 2025	Jan-Sep 2026	Jan-Sep 2025	Jan-Dec 2025
Net profit for the period	726	576	1,967	1,407	2,276
Other comprehensive income					
Items that cannot be restated in profit for the period					
Actuarial gains/losses pertaining to defined-benefit pension plans	162	-4	199	75	165
Tax attributable to items that cannot be restated in profit	-44	1	-58	-23	-45
Items that can later be restated in profit for the period					
Translation differences	783	-190	2,174	-3,508	-4,160
Hedging of net investments	95	-35	290	-651	-754
Cash flow hedges	15	6	12	-8	-5
Tax attributable to items that can be restated in profit	-23	6	-62	136	156
Other comprehensive income for the period, net after tax	988	-216	2,555	-3,980	-4,643
Total comprehensive income for the period	1,714	360	4,522	-2,573	-2,367
Comprehensive income attributable to:					
Parent Company shareholders	1,707	351	4,516	-2,578	-2,373
Non-controlling interests	7	8	7	5	6
Total comprehensive income for the period	1,714	360	4,522	-2,573	-2,367

Condensed consolidated balance sheet

SEK M	Note	September 30 2026	September 30 2025	December 31 2025
Intangible assets		36,375	34,420	33,513
Tangible assets		3,584	3,526	3,469
Right-of-use assets		1,689	1,446	1,470
Financial assets		69	33	34
Deferred tax assets		894	800	792
Total non-current assets		42,611	40,225	39,278
Inventories		7,191	6,736	6,018
Accounts receivable		4,837	4,837	5,782
Other current receivables		1,803	2,142	2,026
Cash and cash equivalents	7	3,157	2,847	3,401
Total current assets		16,987	16,563	17,227
TOTAL ASSETS		59,599	56,789	56,505
Equity		32,711	29,375	29,494
Provisions for pensions, interest-bearing	7	2,322	2,479	2,358
Lease liabilities, long-term	7	1,211	1,017	1,029
Interest-bearing liabilities, long-term	7	6,811	8,545	7,893
Deferred tax liabilities		1,951	1,889	1,754
Other provisions, long-term		450	607	485
Other non-interest-bearing liabilities, long-term		499	519	452
Total long-term liabilities		13,244	15,056	13,970
Lease liabilities, current	7	500	439	452
Interest-bearing liabilities, current	7	2,710	1,428	1,510
Other provisions, current		1,621	1,644	1,564
Accounts payable		2,059	1,924	2,118
Other non-interest-bearing liabilities, current		6,755	6,923	7,398
Total current liabilities		13,644	12,358	13,042
TOTAL EQUITY AND LIABILITIES		59,599	56,789	56,505

Changes in equity for the Group

SEK M	Share capital	Other capital provided	Reserves ¹⁾	Retained earnings	Total	Non-controlling interests	Total equity
Opening balance at January 1, 2026	136	6,789	1,000	21,504	29,430	64	29,494
Total comprehensive income for the period	-	-	2,413	2,103	4,516	7	4,522
Dividend	-	-	-	-1,294	-1,294	-12	-1,305
Closing balance at September 30, 2026	136	6,789	3,413	22,313	32,652	59	32,711
Opening balance at January 1, 2025	136	6,789	5,752	20,328	33,005	205	33,210
Total comprehensive income for the period	-	-	-4,019	1,442	-2,578	5	-2,573
Dividend	-	-	-	-1,253	-1,253	-10	-1,262
Closing balance at September 30, 2025	136	6,789	1,733	20,517	29,175	200	29,375
Opening balance at January 1, 2025	136	6,789	5,752	20,328	33,005	205	33,210
Total comprehensive income for the period	-	-	-4,752	2,378	-2,373	6	-2,367
Dividend	-	-	-	-1,253	-1,253	-14	-1,267
Transactions with non-controlling interests	-	-	-	50	50	-133	-83
Closing balance at December 31, 2025	136	6,789	1,000	21,504	29,430	64	29,494

1) Reserves pertain to cash flow hedges, hedges of net investments and translation differences.

Condensed consolidated cash flow statement

SEK M	Note	Jul-Sep 2026	Jul-Sep 2025	Jan-Sep 2026	Jan-Sep 2025	Jan-Dec 2025
Operating activities						
Operating profit (EBIT)		1,108	952	3,099	2,418	3,789
Add-back of depreciation, amortization and write-downs	4	532	515	1,521	1,596	2,250
Other non-cash items		1	5	2	22	164
Add-back of restructuring costs ¹⁾		41	23	108	326	362
Paid restructuring costs		-50	-57	-176	-187	-338
Financial items ²⁾		-115	-127	-366	-390	-516
Taxes paid		-353	-171	-694	-457	-574
Cash flow before changes in working capital		1,165	1,141	3,495	3,327	5,137
Changes in working capital						
Inventories		-177	78	-692	-883	-465
Operating receivables		408	-132	1,478	834	-218
Operating liabilities		172	-2	-317	-882	-504
Cash flow from operating activities		1,567	1,084	3,965	2,395	3,949
Investing activities						
Acquisition of operations	9	-	-	-1,437	-1,580	-1,663
Investments in intangible assets and tangible assets		-265	-297	-828	-944	-1,314
Divestment of non-current assets		0	5	9	12	17
Cash flow from investing activities		-265	-292	-2,256	-2,513	-2,960
Financing activities						
Change in interest-bearing liabilities		-52	317	-174	1,495	1,000
Depreciation of lease liabilities		134	-123	-388	-375	-501
Change in long-term receivables		5	3	5	3	3
Dividend paid		-	-3	-1,305	-1,263	-1,267
Cash flow from financing activities		-181	193	-1,862	-140	-765
Cash flow for the period		1,121	986	-153	-258	224
Cash and cash equivalents at the beginning of the period		2,052	1,945	3,401	2,961	2,961
Translation differences		-16	-83	-91	144	216
Cash and cash equivalents at the end of the period		3,157	2,847	3,157	2,847	3,401

1) Excluding write-downs on non-current assets

2) Of which interest paid and received in the quarter amounted to SEK-108 M (-118) and other financial items to SEK-7 M (-9)

Note 1 Accounting policies

The Group's interim report has been prepared in accordance with IAS 34 Interim Financial Reporting and the Swedish Annual Accounts Act. For the Parent Company, the report has been prepared in accordance with the Swedish Annual Accounts Act and RFR 2. The accounting policies adopted are consistent with those applied for the 2025 Annual Report and should be read in conjunction with that Annual Report.

Forthcoming amendments to presentation and disclosures (IFRS 18)

IFRS 18 Presentation and Disclosure in Financial Statements will be applied by the Getinge Group from January 1, 2027. The standard will affect the presentation of the income statement, including the classification of income and expenses into the operating, investing and financing categories, as well as introducing new subtotals. For Getinge, the implementation is expected to result in certain reclassifications in the income statement, whereby discount effects on contingent consideration and expenses not directly attributable to the Group's financing will be recognized in the operating category, while other items that were previously recognized in net financial items for the Group have been distributed between the investing and the financing categories. The standard will also impact on the classification of interest in the presentation of the Group's cash flow statement. The standard is not expected to impact on the Group's overall earnings, cash flow or financial position. IFRS 18 also introduces expanded disclosure requirements in the form of management-defined performance measures. The Group is currently analyzing which of its key ratios will be impacted by the definition and how these are to be presented and reconciled against subtotals defined by IFRS.

For practical reasons, the figures in this interim report have not been rounded off, which is why notes and tables may not total correct amounts. Unless otherwise specified, all figures pertain to SEK M and figures in parentheses pertain to the year-earlier period. The interim report provides alternative performance measures for monitoring the Group's operations.

Note 2 Net sales

Net sales, SEK M	Jul-Sep 2026	Jul-Sep 2025	Jan-Sep 2026	Jan-Sep 2025	Jan-Dec 2025
Capital goods	2 498	2,675	7 071	7,785	11,968
Recurring revenue					
Product sales	4 181	3,873	12 151	12,016	16,185
Service assignments incl. spare parts	1 767	1,678	5 048	4,983	6,815
Total recurring revenue	5 948	5,551	17 199	16,999	23,001
Total	8 446	8,226	24 270	24,783	34,969

Net sales, SEK M	Jul-Sep 2026	Jul-Sep 2025	Jan-Sep 2026	Jan-Sep 2025	Jan-Dec 2025
Revenue recognized at a point in time					
Acute Care Therapies	4 199	4,043	12 204	12,752	17,499
Life Science	909	831	2 607	2,434	3,386
Surgical Workflows	2 273	2,249	6 465	6,466	9,626
Total revenue recognized at a point in time	7 380	7,124	21 277	21,652	30,512
Revenue recognized over time					
Acute Care Therapies					
Service	291	273	802	777	1,068
Profit from ongoing projects	5	0	5	-	-
Other revenue recognized over time	22	23	70	66	108
Total Acute Care Therapies	317	296	877	843	1,176
Life Science					
Service	68	63	203	198	260
Profit from ongoing projects	89	203	360	539	852
Other revenue recognized over time	0	0	0	0	0
Total Life Science	157	266	563	737	1,112
Surgical Workflows					
Service	525	464	1 400	1,356	1,870
Profit from ongoing projects	23	37	41	98	139
Other revenue recognized over time	43	39	113	99	160
Total Surgical Workflows	591	540	1 554	1,552	2,170
Total revenue recognized over time	1 065	1,102	2 993	3,132	4,457

Total revenue recognized at a point in time and over time	8 446	8,226	24 270	24,783	34,969
--	--------------	--------------	---------------	---------------	---------------

For further information about the distribution of sales for each business area, see pages 6-8.

Note 3 Segment overview

	Jul-Sep 2026	Jul-Sep 2025	Jan-Sep 2026	Jan-Sep 2025	Jan-Dec 2025
Net sales, SEK M					
Acute Care Therapies	4,516	4,339	13,081	13,594	18,675
Life Science	1,066	1,097	3,170	3,171	4,498
Surgical Workflows	2,864	2,789	8,019	8,018	11,796
Total	8,446	8,226	24,270	24,783	34,969

	Jul-Sep 2026	Jul-Sep 2025	Jan-Sep 2026	Jan-Sep 2025	Jan-Dec 2025
Gross profit, SEK M					
Acute Care Therapies	2,568	2,339	7,715	7,586	10,420
Life Science	382	370	1,148	1,117	1,556
Surgical Workflows	1,158	1,107	3,266	3,148	4,679
Total	4,108	3,815	12,130	11,851	16,654

	Jul-Sep 2026	Jul-Sep 2025	Jan-Sep 2026	Jan-Sep 2025	Jan-Dec 2025
Operating profit (EBIT), SEK M					
Acute Care Therapies	891	690	2,698	2,157	3,021
Life Science	110	125	323	261	470
Surgical Workflows	246	238	466	337	773
Group functions and other (incl. eliminations) ¹⁾	-139	-100	-388	-337	-474
Operating profit (EBIT)	1,108	952	3,099	2,418	3,789
Net financial items	-134	-163	-401	-480	-644
Profit after financial items	974	789	2,698	1,938	3,145

1) Group functions and other refer mainly to central functions such as finance, communication, HR and other items, such as eliminations.

	Jul-Sep 2026	Jul-Sep 2025	Jan-Sep 2026	Jan-Sep 2025	Jan-Dec 2025
Net sales, SEK M					
EMEA	2,997	2,848	8,652	8,317	12,340
<i>of which, Sweden</i>	134	116	440	439	648
Americas	3,886	3,723	11,213	11,617	15,686
<i>of which, USA</i>	3,536	3,371	10,177	10,500	14,157
APAC	1,563	1,655	4,405	4,849	6,943
Total	8,446	8,226	24,270	24,783	34,969

Note 4 Depreciation, amortization and write-downs

SEK M	Jul-Sep 2026	Jul-Sep 2025	Jan-Sep 2026	Jan-Sep 2025	Jan-Dec 2025
Acquired intangible assets	-96	-93	-276	-294	-434
Intangible assets	-140	-148	-404	-462	-643
Right-of-use assets	-140	-128	-405	-392	-523
Tangible assets	-155	-147	-436	-448	-650
Total	-532	-515	-1,521	-1,596	-2,250
<i>Write-downs included in total</i>	-6	-4	-7	-23	-166

SEK M	Jul-Sep 2026	Jul-Sep 2025	Jan-Sep 2026	Jan-Sep 2025	Jan-Dec 2025
Cost of goods sold	-238	-235	-687	-719	-953
Selling expenses	-171	-160	-491	-498	-705
Administrative expenses	-95	-100	-277	-305	-405
Research and development costs	-27	-21	-68	-55	-175
Restructuring costs	-	0	-	-19	-12
Total	-532	515	-1,521	-1,596	-2,250
<i>Write-downs included in total</i>	-6	-4	-7	-23	-166

Note 5 Quarterly results

SEK M	Jul-Sep 2026	Apr-Jun 2026	Jan-Mar 2026	Oct-Dec 2025	Jul-Sep 2025	Apr-Jun 2025	Jan-Mar 2025	Oct-Dec 2024
Net sales	8,446	8,381	7,443	10,186	8,226	8,238	8,320	11,071
Cost of goods sold	-4,338	-3,965	-3,837	-5,382	-4,411	-4,296	-4,225	-6,018
Gross profit	4,108	4,416	3,606	4,803	3,815	3,941	4,095	5,053
Operating expenses	-3,000	-3,132	-2,899	-3,432	-2,863	-3,074	-3,497	-3,969
Operating profit (EBIT)	1,108	1,284	707	1,371	952	867	598	1,084
Net financial items	-134	-133	-135	-164	-163	-147	-170	-173
Profit after financial items	974	1,151	573	1,207	789	721	428	911
Taxes	-248	-312	-170	-338	-214	-194	-124	-243
Net profit for the period	726	839	402	869	576	527	304	668

Note 6 Adjustment items

Adjusted EBITA, SEK M	Jul-Sep 2026	Jul-Sep 2025	Jan-Sep 2026	Jan-Sep 2025	Jan-Dec 2025
Acute Care Therapies	975	763	2,940	2,624	3,763
Life Science	125	141	367	318	490
Surgical Workflows	284	263	596	453	1,077
Group functions and other (incl. eliminations)	-106	-89	-324	-323	-450
Total	1,278	1,079	3,580	3,071	4,880

Adjustments of EBITA, SEK M	Jul-Sep 2026	Jul-Sep 2025	Jan-Sep 2026	Jan-Sep 2025	Jan-Dec 2025
Specification of items affecting comparability that impact EBITA					
Restructuring costs, Acute Care Therapies	-26	-16	-39	-282	-293
Restructuring costs, Life Science	-2	-3	-7	-16	-22
Restructuring costs, Surgical Workflows	-13	-4	-62	-48	-59
Write-down of R&D, Acute Care Therapies	-	-	-	-	-28
Write-down of R&D, Surgical Workflows	-	-	-	-	-107
Increased provision for contingent consideration, Acute Care Therapies ¹⁾	-	-	-	-	-179
Dissolution of provisions for contingent consideration, Life Science ¹⁾	-	-	-	-	55
Other, Acute Care Therapies	-	-	-33	-	-
Group functions and other (incl. eliminations)	-33	-11	-64	-14	-24
Total	-74	-33	-205	-359	-656
Items affecting comparability per segment					
Acute Care Therapies	-26	-16	-72	-282	-500
Life Science	-2	-3	-7	-16	33
Surgical Workflows	-13	-4	-62	-48	-166
Group functions and other (incl. eliminations)	-33	-11	-64	-14	-24
Total	-74	-33	-205	-359	-656

1) Reported in Other operating income and operating expenses

EBITA, SEK M	Jul-Sep 2026	Jul-Sep 2025	Jan-Sep 2026	Jan-Sep 2025	Jan-Dec 2025
Acute Care Therapies	949	748	2,868	2,342	3,264
Life Science	123	138	361	302	523
Surgical Workflows	271	260	534	405	911
Group functions and other (incl. eliminations)	-139	-100	-388	-337	-474
Total	1,204	1,045	3,375	2,712	4,223

Adjustments of EBIT, SEK M	Jul-Sep 2026	Jul-Sep 2025	Jan-Sep 2026	Jan-Sep 2025	Jan-Dec 2025
Items affecting comparability that impact EBITA (according to above)	-74	-33	-205	-359	-656
Items affecting comparability that impact EBIT but not EBITA ¹⁾	-	-	-	-	-48
Total	-74	-33	-205	-359	-704

1) Write-down of acquired intangible assets, Surgical Workflows. Reported in Operating expenses

	Jul-Sep 2026	Jul-Sep 2025	Jan-Sep 2026	Jan-Sep 2025	Jan-Dec 2025
Effect of adjustment of tax, SEK M					
Amortization and write-down of acquired intangible assets ¹⁾	96	93	276	294	386
Items affecting comparability	74	33	205	359	704
Adjustment items, total	170	127	481	653	1,091
Tax on adjustment items ²⁾	-47	-35	-133	-180	-273
Adjustment for tax items affecting comparability	-	-	-	-	-
Total	-47	-35	-133	-180	-273

1) Excluding write-downs classified as items affecting comparability
2) Tax effect on tax deductible adjustment items

Note 7 Consolidated net interest-bearing debt

SEK M	September 30 2026	September 30 2025	December 31 2025
Interest-bearing liabilities, current	2,710	1,428	1,510
Interest-bearing liabilities, long-term	6,811	8,545	7,893
Provisions for pensions, interest-bearing	2,322	2,479	2,358
Lease liabilities, current	500	439	452
Lease liabilities, long-term	1,211	1,017	1,029
Interest-bearing liabilities	13,554	13,908	13,241
Less cash and cash equivalents	-3,157	-2,847	-3,401
Net interest-bearing cash/debt	10,397	11,061	9,840

Note 8 Key figures for the Group

	Jul-Sep 2026	Jul-Sep 2025	Jan-Sep 2026	Jan-Sep 2025	Jan-Dec 2025
Financial and operative key figures					
Key figures based on Getinge's financial targets					
Adjusted earnings per share ¹⁾ , SEK	3.10	2.42	8.48	6.84	11.29
Growth in adjusted earnings per share ¹⁾ , %	28.1	7.9	24.0	6.1	-3.7
Other operative and financial key figures					
Organic growth in order intake, %	2.6	4.7	4.2	4.0	3.5
Organic growth in net sales, %	2.1	9.5	2.5	6.6	4.9
Gross margin, %	48.6	46.4	50.0	47.8	47.6
Selling expenses, % of net sales	17.2	17.2	18.1	18.1	17.3
Administrative expenses, % of net sales	13.3	13.2	14.2	13.7	13.1
Research and development costs, gross as a % of net sales	5.8	5.5	6.1	5.9	6.0
Operating margin, %	13.1	11.6	12.8	9.8	10.8
EBITDA, SEK M	1,636	1,468	4,620	4,014	6,039
Average number of shares, thousands	272,370	272,370	272,370	272,370	272,370
Number of shares at the end of the period, thousands	272,370	272,370	272,370	272,370	272,370
Interest-coverage ratio, multiple			13.2	11.6	11.2
Net debt/equity ratio, multiple			0.32	0.38	0.33
Net debt/Rolling 12m adjusted EBITDA, multiple			1.5	1.6	1.5
Capital employed, SEK M			41,135	41,417	40,934
Return on capital employed, %			12.2	11.6	11.0
Return on equity, %			9.2	6.8	7.5
Equity/assets ratio, %			54.9	51.7	52.2
Equity per share, SEK			120.10	107.85	108.28
Number of employees			11,847	11,794	11,670

1) Before and after dilution

Alternative performance measures

Alternative performance measures refer to financial measures used by the company's management and investors to evaluate the Group's earnings and financial position and that cannot be directly read or derived from the financial statements. These financial measures are intended to facilitate analysis of the Group's performance. Accordingly, the alternative performance measures should be considered a supplement to the financial statements prepared in accordance with IFRS. The financial measures recognized in this report may differ from similar measures used by other companies.

	Jul-Sep 2026	Jan-Sep 2026
Calculation of organic net sales		
Net sales 2025	8,226	24,783
<i>Adjustment of:</i>		
Divested operations and products as well as products being phased out, in the comparative period	-74	-196
Net sales 2025 adjusted for divested operations and products	8,152	24,587
Net sales 2026	8,446	24,270
<i>Adjustment of:</i>		
Currency impact	-82	1,025
Acquired and divested operations and products as well as products being phased out.	-38	-93
Net sales organic 2026	8,326	25,201

	Jul-Sep 2026	Jul-Sep 2025	Jan-Sep 2026	Jan-Sep 2025	R12 Sep 2026	Jan-Dec 2025
Adjusted gross profit, SEK M						
Gross profit	4,108	3,815	12,130	11,851	16,933	16,654
<i>Add-back of:</i>						
Depreciation, amortization and write-downs of intangible assets and tangible assets	235	235	687	719	921	953
Other items affecting comparability	-	-	-	-	-	-
Adjustment for write-downs included in other items affecting comparability	-	-	-	-	-	-
Adjusted gross profit	4,343	4,051	12,817	12,570	17,854	17,607

	Jul-Sep 2026	Jul-Sep 2025	Jan-Sep 2026	Jan-Sep 2025	R12 Sep 2026	Jan-Dec 2025
Adjusted EBITDA, SEK M						
Operating profit (EBIT)	1,108	952	3,099	2,418	4,470	3,789
<i>Add-back of:</i>						
Depreciation, amortization and write-downs of intangible assets and tangible assets	433	422	1,245	1,302	1,807	1,864
Amortization and write-down of acquired intangible assets	96	93	276	294	368	386
Other items affecting comparability	-	-	33	-	340	307
Acquisition and restructuring costs	74	33	172	359	211	397
Adjustment for write-downs included in other items affecting comparability and restructuring costs	-	0	-	-19	-143	-162
Adjusted EBITDA	1,711	1,501	4,825	4,353	7,054	6,581

	Jul-Sep 2026	Jul-Sep 2025	Jan-Sep 2026	Jan-Sep 2025	R12 Sep 2026	Jan-Dec 2025
Adjusted EBITA, SEK M						
Operating profit (EBIT)	1,108	952	3,099	2,418	4,470	3,789
<i>Add-back of:</i>						
Amortization and write-down of acquired intangible assets	96	93	276	294	368	386
Other items affecting comparability	-	-	33	-	340	307
Acquisition and restructuring costs	74	33	172	359	211	397
Adjusted EBITA	1,278	1,079	3,580	3,071	5,389	4,880

	Jul-Sep 2026	Jul-Sep 2025	Jan-Sep 2026	Jan-Sep 2025	R12 Sep 2026	Jan-Dec 2025
Adjusted EBIT, SEK M						
Operating profit (EBIT)	1,108	952	3,099	2,418	4,470	3,789
<i>Add-back of:</i>						
Other items affecting comparability	-	-	33	-	340	307
Acquisition and restructuring costs	74	33	172	359	211	397
Adjusted EBIT	1,182	986	3,304	2,776	5,021	4,494

	Jul-Sep 2026	Jul-Sep 2025	Jan-Sep 2026	Jan-Sep 2025	R12 Sep 2026	Jan-Dec 2025
Adjusted net profit for the period, SEK M						
Net profit for the period	726	576	1,967	1,407	2,836	2,276
<i>Add-back of:</i>						
Amortization and write-down of acquired intangible assets	96	93	276	294	368	386

Other items affecting comparability	-	-	33	-	340	307
Acquisition and restructuring costs	74	33	172	359	211	397
Tax items affecting comparability	-	-	-	-	-	-
Tax on add-back items	-47	-35	-133	-180	-227	-273
Adjusted net profit for the period	850	668	2,316	1,880	3,529	3,093

The calculation of adjusted earnings per share, before and after dilution, attributable to Parent Company shareholders, is based on the following information:

	Jul-Sep 2026	Jul-Sep 2025	Jan-Sep 2026	Jan-Sep 2025	R12 Sep 2026	Jan-Dec 2025
Earnings (numerator), SEK M						
Adjusted net profit for the period	850	668	2,316	1,880	3,529	3,093
Adjusted net profit for the period attributable to non-controlling interest	-6	-10	-6	-17	-6	-17
Adjusted net profit for the period attributable to the Parent Company shareholders, which forms the basis for calculation of adjusted earnings per share	843	658	2,310	1,863	3,522	3,076
Number of shares (denominator)						
Weighted average number of ordinary shares for calculation of adjusted earnings per share (thousands)	272,370	272,370	272,370	272,370	272,370	272,370
Adjusted earnings per share, SEK	3.10	2.42	8.48	6.84	12.93	11.29

The calculation of adjusted EBITA margin, adjusted for currency impact and tariff costs is based on the following information:

	Jul-Sep 2026	Jan-Sep 2026	R12 Sep 2026
Adjusted EBITA (numerator), SEK M			
Adjusted EBITA	1,278	3,580	5,389
Add-back of:			
Currency impact	-36	159	474
Tariffs costs ¹⁾	62	-78	70
Adjusted EBITA, adjusted for currency impact and tariff costs	1,305	3,661	5,933
Net sales (denominator)			
Net sales	8,446	24,270	34,455
Add-back of:			
Currency impact	-82	1,025	2,048
Net sales, adjusted for currency impact	8,364	25,294	36,504
Adjusted EBITA margin, adjusted for currency impact and tariff costs, %	15.6	14.5	16.3
Adjusted EBITA margin, adjusted for only tariff costs, %	15.9	14.4	15.8

1) Net of tariff costs and tariff refunds

The calculation of adjusted EBITA margin, adjusted for currency impact and tariff refunds is based on the following information:

	Jul-Sep 2026	Jan-Sep 2026	R12 Sep 2026
Adjusted EBITA (numerator), SEK M			
Adjusted EBITA	1,278	3,580	5,389
Add-back of:			
Currency impact	-36	159	474
Tariff refunds	-45	-381	-381
Adjusted EBITA, adjusted for currency impact and tariff refunds	1,197	3,358	5,483
Net sales (denominator)			
Net sales	8,446	24,270	34,455
Add-back of:			
Currency impact	-82	1,025	2,048
Net sales, adjusted for currency impact	8,364	25,294	36,504

Adjusted EBITA margin, adjusted for currency impact and tariff refunds, %	14.3	13.3	15.0
Adjusted EBITA margin, adjusted for only tariff refunds, %	14.6	13.2	14.5

Note 9 Acquisitions

Acquisitions 2026

No acquisitions took place during the third quarter that had a material impact on the Group's financial earnings and position.

Contingent considerations

Getinge signed agreements on contingent considerations in connection with acquisitions of assets and subsidiaries. Liabilities for these additional purchase prices are measured at fair value through profit or loss at Level 3 of the fair value hierarchy. The additional purchase prices are contingent on securing government approval for the acquired product development projects and contingent on the earnings performance of the acquired businesses. Future cash flows are discounted if the planned payment date exceeds 12 months. Assessments of future cash flows related to the contingent consideration are regularly reviewed by company management and recognized at fair value. The discount effect is recognized in profit or loss under financial items on an ongoing basis.

	September 30 2026	September 30 2025	December 31 2025
Contingent considerations			
Opening balance	1,444	3,280	3,280
Dissolution of provision	-	-	-55
Fair value adjustments recognized in profit or loss	-	5	184
Payments	-1,040	-1,599	-1,599
Discount effect	22	60	77
Translation differences	64	-401	-443
Closing balance	490	1,344	1,444

Parent Company financial statements

Condensed Parent Company's income statement

SEK M	Jul-Sep 2026	Jul-Sep 2025	Jan-Sep 2026	Jan-Sep 2025	Jan-Dec 2025
Net sales	84	75	263	257	348
Administrative expenses	-135	-86	-373	-282	-397
Operating profit/loss	-51	-11	-110	-25	-49
Result from participations in Group companies ¹⁾	58	43	1,487	2,134	2,134
Interest income and other similar income ²⁾	1	8	8	45	55
Interest expenses and other similar expenses ²⁾	-50	-54	-150	-167	-220
Profit after financial items	-42	-14	1,235	1,987	1,920
Appropriations	0	-	0	-	60
Taxes	10	2	11	-6	-24
Net profit/loss for the period³⁾	-32	-12	1,246	1,981	1,956

1) Primarily refers to dividends from Group companies that take place on an ongoing basis throughout the year

2) Interest income and other similar income, and interest expenses and other similar expenses include exchange-rate gains and losses attributable to the translation of financial receivables and liabilities measured in foreign currencies

3) Comprehensive income for the period corresponds to net profit for the period

Condensed Parent Company's balance sheet

SEK M	September 30 2026	September 30 2025	December 31 2025
Assets			
Tangible assets	1	1	1
Participations in Group companies	31,604	31,572	31,572
Deferred tax assets	120	104	97
Current receivables from Group companies	817	1,222	974
Current receivables	84	80	40
Cash and bank balances	0	2	2
Total assets	32,626	32,981	32,687
Equity and liabilities			
Equity	26,325	26,397	26,372
Long-term liabilities	4,645	5,793	5,394
Other provisions	32	25	18
Current liabilities to Group companies	2	8	7
Current liabilities	1,623	758	896
Total equity and liabilities	32,626	32,981	32,687

Definitions

Financial terms

Adjusted earnings per share: Adjusted net profit for the period attributable to Parent Company shareholders in relation to average number of shares.

Adjusted EBIT: Operating profit (EBIT) with add-back of acquisition and restructuring costs, and other items affecting comparability.

Adjusted EBITA: EBITA with add-back of acquisition and restructuring costs and other items affecting comparability.

Adjusted EBITDA: EBITDA with add-back of acquisition and restructuring costs and other items affecting comparability.

Adjusted gross profit: Gross profit with add-back of depreciation, amortization and write-downs and other items affecting comparability.

Adjusted net profit for the period: Net profit for the period with add-back of amortization and write-down of acquired intangible assets, acquisition and restructuring costs, other items affecting comparability and tax effect of add-back of income-statement items.

Adjusted profit before tax: Profit before tax for the period with add-back of amortization and write-down of acquired intangible assets, acquisition and restructuring costs and other items affecting comparability.

Capital employed: Average total assets with add-back of cash and cash equivalents, other provisions, accounts payable and other non-interest-bearing liabilities.

Capital goods: Durable products that are not consumed when used.

Currency transaction effect: Exchange of current year's volumes of foreign currency at this year's exchange rates, compared with the exchange rates in the preceding year.

Earnings per share: Net profit attributable to Parent Company shareholders in relation to average number of shares.

EBIT: Operating profit.

EBITA margin: EBITA in relation to net sales.

EBITA: Operating profit (EBIT) before add-back of amortization and write-down of acquired intangible assets.

EBITDA margin: EBITDA in relation to net sales.

EBITDA: Operating profit (EBIT) with add-back of amortization, depreciation and write-downs.

Equity per share: Equity in relation to the number of shares at the end of the period.

Equity/assets ratio: Equity in relation to total assets.

Free cash flow: Cash flow from operating activities and investing activities, excluding acquisitions and divestment of operations.

Gross margin: Gross profit in relation to net sales.

Interest-coverage ratio: Rolling 12 months' adjusted EBITDA in relation to rolling 12 months' net interest.

Items affecting comparability: Acquisition and restructuring costs and other items affecting comparability. Other items affecting comparability are significant revenue/expenses that impact comparability between accounting periods. These items include, but are not limited to, write-downs, disputes and major gains and losses attributable to divestments of assets or businesses.

Net debt/equity ratio: Net interest-bearing debt in relation to equity.

Operating liabilities: Accounts payable, other provisions and other non-interest-bearing liabilities (contract liabilities, non-interest-bearing provisions for pensions and similar obligations, accrued expenses and deferred income as well as other liabilities).

Operating margin: Operating profit (EBIT) in relation to net sales.

Operating receivables: Accounts receivable and other current receivables (contract assets, prepaid expenses and accrued income, and other receivables).

Organic change: A financial change adjusted for currency, acquisitions and divestments of operations.

Adjusted to the following from first quarter of 2026:

A financial change adjusted for currency, acquisitions and divestments of operations *and phase-out of product categories*.

Recurring revenue: Revenue from sales of products that are continuously consumed as well as service, spare parts and similar items.

Return on capital employed: Rolling 12 months' adjusted EBIT in relation to capital employed.

Return on equity: Rolling 12 months' profit after tax in relation to average equity.

Sustainability terms

Double materiality assessment: The process of identifying an organization's impacts on people and the environment and the sustainability-related financial risks and opportunities for the organization. The results are also used to determine whether a sustainability topic is to be included in the company's sustainability report.

Employee engagement: The engagement score in Getinge's employee survey.

ESRS: European Sustainability Reporting Standards.

Online customer training: The number of training courses held for customers. The total number of times a customer has completed an e-learning course or participated in a training webinar.

REC (Renewable Energy Certificates): Used to certify that electricity was generated from renewable sources.

Scope 1 & 2: Carbon emissions from production (in ton CO₂ equivalents). Scope 1 includes emissions from oil and gas consumption. Emissions from Getinge's vehicle fleet are excluded in the interim report but the amounts for the full-year are presented in the Sustainability Report. Scope 2 includes emissions from electricity, heating and cooling. Emissions from leased premises are excluded in the interim report but the amounts for the full-year are presented in the Sustainability Report.

Scope 3: Includes other indirect emissions, both upstream and downstream in the value chain, arising from activities such as freight transport, purchased goods and services, as well as emissions from the use of products sold.

WRAR (Work Related Accident Rate): The number of work related accidents divided by the number of hours worked, normalized by multiplying by 200,000 hours.

Medical terms

Autoclave: A device to eliminate microorganisms on surgical instruments, usually by high temperature with steam.

Cardiopulmonary: Pertaining or belonging to both heart and lung.

Cardiovascular: Pertaining or belonging to both heart and blood vessels.

DPTE®-BetaBags: Bag that ensures contamination-free transfer of components.

ECMO: Extracorporeal membrane oxygenation, meaning oxygenation outside the body through a membrane. Put simply, a modified cardiac and respiratory machine

that exchanges oxygen and carbon dioxide, like an artificial lung.

Endoscope: Equipment for visual examination of the body's cavities, such as the stomach.

Endovascular: Vascular treatment using catheter technologies.

EVH Endoscopic Vessel Harvesting is a minimally invasive technique for removing blood vessels, for example during coronary artery bypass surgery.

Extracorporeal life support (ECLS): Oxygenation of the patient's blood outside the body (extracorporeal) using advanced medical technology.

Grafts: Artificial vascular implants.

Hemodynamic monitoring: Monitoring the balance between blood pressure and blood flow.

Low temperature sterilization: A device used to sterilize surgical instruments which cannot be sterilized with high temperature steam. It is mainly used for instruments used in the minimal invasive and robotic surgery.

NAVA: Neurally Adjusted Ventilatory Assist (NAVA) identifies the electric activity that activates the diaphragm and using these signals adapts the ventilation to the patient's respiratory rhythm.

Perfusionist: A healthcare professional who operates the heart-lung machine during surgery.

Stent: A tube for endovascular widening of blood vessels.

Vascular intervention: A medical procedure conducted through vascular puncturing instead of using an open surgery method.

Ventilator: Medical device to help patients breathe.

Vessel harvesting: The name of the process for removing blood vessels from the body.

WIS: The product category of washers, isolators and sterilizers.

Geographic areas

Americas: North, South and Central America.

APAC: Asia and Pacific (excluding Middle East).

EMEA: Europe, Middle East and Africa.

Teleconference

A teleconference with President & CEO Mattias Perjos and CFO Agneta Palmér will be held on October 21, 2026 at 10:00–11:00 a.m. CEST.

Fund managers, analysts and the media are invited to the teleconference.

Register via <https://events.inderes.com/getinge/q3-2026/dial-in> to participate in the teleconference. After registering, you will receive a telephone number and a conference ID to log in to the teleconference. You can ask questions verbally at the teleconference.

A presentation will be held during the telephone conference. To access the presentation, click on <https://getinge.events.inderes.com/q3-2026>. A recording will be available via <https://getinge.events.inderes.com/q3-2026> for three years.

Financial information

Updated information on, for example, the Getinge share and corporate governance is available on Getinge's website www.getinge.com. The Annual Report, year-end report and interim reports are published in Swedish and English and are available for download at www.getinge.com. The preliminary dates for financial communication are provided below:

January 26, 2027	Q4 and Year-end report 2026
April 20, 2027	Q1 Report 2027
April 20, 2027	Annual General Meeting
July 16, 2027	Q2 Report 2027
October 19, 2027	Q3 Report 2027
January 25, 2028	Q4 and Year-end report 2027

Contact

David Kördel, Head of Investor Relations
+46 (0)10 335 0077
david.kordel@getinge.com

This information is such that Getinge AB (publ) is obligated to disclose in accordance with the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact persons set out above, on October 21, 2026 at 8:00 a.m. CEST.

With a firm belief that every person and community should have access to the best possible care, Getinge provides hospitals and life science institutions with products and solutions that aim to improve clinical results and optimize workflows. The offering includes products and solutions for intensive care, cardiovascular procedures, operating rooms, sterile reprocessing and life science. Getinge employs about 12,000 people worldwide and the products are sold in more than 135 countries.

Getinge has been listed on Nasdaq OMX Stockholm, Nordic Large Cap since 1993.

Getinge AB (publ) | Lindholmspiren 7A, 417 56 Gothenburg, Sweden | Tel: +46 (0)10 335 0000 | E-mail: info@getinge.com | Corp. Reg. No.: 556408-5032 | www.getinge.com